Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out

After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention

M&A Explorer | Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022

Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking

At its core, the smart city is about people and improving the quality of our everyday lives.

Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity

Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking.

The value of healthcare M&A in H1 surpassed pre-pandemic levels

Increasing cooperation between global PE players is pushing up price tags  

New challenges may lie ahead for the pharmaceutical industry

Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery.  

Companies seeking mergers can expect scrutiny and litigation